March 10, 2020

Robert J. Delaversano
Principal Accounting Officer
OncoSec Medical Inc
24 North Main Street
Pennington, NJ 08534

       Re: OncoSec Medical Inc
           Form 10-K for the fiscal year ended July 31, 2019
           Filed October 28, 2019
           Form 10-Q for the quarterly period ended October 31, 2019
           Filed December 13, 2019
           File No. 000-54318

Dear Mr. Delaversano:

        We have reviewed your February 27, 2020 response to our comment letter
and have the
following comment. In our comment, we may ask you to provide us with
information so we may
better understand your disclosure.

       Please respond to this comment within ten business days by providing the
requested
information or advise us as soon as possible when you will respond. If you do
not believe our
comment applies to your facts and circumstances, please tell us why in your
response.

       After reviewing your response to this comment, we may have additional
comments. Unless we note otherwise, our references to a prior comment are to
the comment in
our February 13, 2020 letter.

Form 10-Q for the Quarterly Period Ended October 31, 2019

Financial Statements
Notes to Financial Statements
Note 8 - Commitments and Contingencies
Note 8 -License Agreement and Services Agreement, page 23

1.    We refer to your response to prior comment 1, and your statement that you
made the
      decision to exclude the minimum royalty percentage, as filed on Form 8-K
as Exhibit 10.3
      on October 11, 2019, on the basis that such information is (i) not
material and (ii) would
      be competitively harmful if publicly disclosed. Please note that material
information
      about your material agreements must be disclosed. Although you may
request confidential
 Robert J. Delaversano
OncoSec Medical Inc
March 10, 2020
Page 2
         treatment for specific provisions in these agreements that may cause
substantial
         competitive harm, your disclosure should provide investors with
information regarding the
         material provisions of those agreements that would allow investors to
evaluate the
         agreements in the context of your business. We reiterate our comment
in part with regard
         to the disclosure of "up to 20% royalties": Please disclose the
minimum royalty rate and a
         royalty range that does not exceed a 10-point range.
       You may contact Lisa Vanjoske at 202-551-3614 or Daniel Gordon at
202-551-3486 if
you have questions regarding the comment.



FirstName LastNameRobert J. Delaversano                      Sincerely,
Comapany NameOncoSec Medical Inc
                                                             Division of
Corporation Finance
March 10, 2020 Page 2                                        Office of Life
Sciences
FirstName LastName